We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.64 | -1.01% | 161.00 | 163.6923 | 161.14 | 162.73 | 5,178,771 | 23:45:06 |
From May 2019 to May 2024
By Colin Kellaher
AbbVie Inc.'s Allergan unit on Thursday said it filed a new-drug application with the U.S. Food and Drug Administration for AGN-190584, an ophthalmic solution for the treatment of the common vision condition presbyopia.
Allergan said AGN-190584, if approved, would be the first eye drop to treat presbyopia, a progressive condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40.
Allergan, which noted that roughly 128 million adults in the U.S. experience presbyopia, said it expects the FDA to act on the application by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 25, 2021 08:43 ET (13:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
